BRIEF published on 03/31/2026 at 13:12, 1 month 9 days ago Poxel sells the PXL770 to Scynexis for a potential value of $196 million Financial Agreement Poxel PXL770 SCYNEXIS Polycystic Kidney Disease
BRIEF published on 03/31/2026 at 13:12, 1 month 9 days ago Poxel Sells PXL770 to Scynexis for Up to $196 Million Biopharmaceutical Poxel PXL770 SCYNEXIS ADPKD
PRESS RELEASE published on 03/31/2026 at 13:07, 1 month 9 days ago Inside Information / Operations of the issuer (acquisitions, sales...) Poxel announces sale of PXL770 for up to $196 million to SCYNEXIS. PXL770 targets ADPKD. Agreement includes upfront payment, development and commercial milestones. Phase 2 study planned for Q4 2026 Milestones Poxel PXL770 SCYNEXIS ADPKD
BRIEF published on 03/25/2026 at 22:03, 1 month 14 days ago Poxel Secures Additional Financing Through New Tranche D PDR Bonds Financing Continuation Plan Poxel IPF Partners Tranche D PDR
PRESS RELEASE published on 03/25/2026 at 21:58, 1 month 14 days ago Inside Information / News release on accounts, results Poxel confirms drawdown under Tranche D PDR bond issue for €3.75 million with IPF as part of continuation plan validated by Lyon Commercial Court. Key details and financing prospects outlined Financing Opportunities Poxel IPF Partners Tranche D PDR
BRIEF published on 02/03/2026 at 08:45, 3 months 6 days ago Poxel Establishes Equity Line with IRIS Capital Financing Recovery Plan Equity Line Poxel IRIS Capital
PRESS RELEASE published on 02/03/2026 at 08:40, 3 months 6 days ago Inside Information / Other news releases Poxel announces implementation of equity line with IRIS Capital as part of recovery plan. New financing structure to enhance financial foundation Financial Structure Recovery Plan Equity Line Poxel IRIS Capital
BRIEF published on 01/30/2026 at 08:02, 3 months 10 days ago Commercial Court of Lyon Approves Poxel's Recovery Plan Financial Strategy Recovery Plan Commercial Court Poxel Debts Settlement
PRESS RELEASE published on 01/30/2026 at 07:57, 3 months 10 days ago Inside Information / Other news releases Poxel SA receives approval for recovery plan from Commercial Court of Lyon, closing reorganisation proceedings and focusing on business development, cost optimization, settlement of liabilities, and financial strengthening Business Development Recovery Plan Financial Restructuring Poxel SA Commercial Court Of Lyon
BRIEF published on 12/11/2025 at 19:47, 4 months 28 days ago Poxel Reports Outcomes of General Meeting and Looks Ahead Shareholders General Meeting Biopharmaceutical Recovery Plan Poxel
Published on 05/09/2026 at 01:30, 16 hours 36 minutes ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 18 hours 6 minutes ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 20:38, 21 hours 27 minutes ago EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 22 hours 53 minutes ago EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 23 hours 3 minutes ago Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/07/2026 at 19:15, 1 day 22 hours ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:06, 1 day 22 hours ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 18:17, 1 day 23 hours ago DESCRIPTION OF THE LOUIS HACHETTE GROUP SHARE BUYBACK PROGRAM 2026-2027
Published on 05/07/2026 at 17:45, 2 days ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
